EMA Application withdrawn: Rayoqta (abicipar pegol) — Allergan Pharmaceuticals International Limited

View source ↗

Summary

The EMA withdrew the application for Rayoqta (abicipar pegol) by Allergan for macular degeneration.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• Rayoqta (abicipar pegol)

Snippet

Status: Application withdrawn. Therapeutic area: Macular Degeneration. MAH: Allergan Pharmaceuticals International Limited